myasthenia%20gravis
MYASTHENIA GRAVIS
Myasthenia gravis is an autoimmune neurological disorder caused by autoantibodies against the acetylcholine receptor or against a receptor-associated protein, muscle-specific tyrosine kinase (MuSK-Ab).
The autoimmune attack at the muscle endplate leads to failure of neuromuscular transmission and eventually muscle weakness.
In the active phase of the disease, symptoms typically fluctuates and then become severe; myasthenic crisis occur in this phase.
In the stable/inactive phase, symptoms are stable but still persist; it usually worsen attributable to infection, fatigue, tapering of medications or other identifiable factors.
In the burnt-out phase, remission may occur wherein patients are on immunotherapy and symptom-free, or may even be off medications.
In 15-20 years, if the symptoms left untreated, patient's weakness becomes fixed wherein the most severely affected muscles become atrophic.

Myasthenia Gravis Drug Information

Drug Information

Indication: Rheumatic fever, RA, allergic diseases, nephritic syndrome, bronchial asthma & other corticosteroid-indica...

Indication: Prophylaxis of acute organ rejection in patients receiving allogeneic renal, cardiac & hepatic transplants...

Indication: Immunosuppressant antimetabolite, organ transplants, autoimmune chronic active hepatitis, severe RA, SLE, chro...

Indication: In combination w/ ciclosporin microemulsion & corticosteroids for prophylaxis of acute transplant rejectio...

Indication: Allergic, collagen, dermatological, GI, desquamative gingivitis, hematologic, tuberculous meningitis, ophth, r...

Indication: Bronchial asthma, allergic disease, RA, juvenile RA, rheumatoid myocarditis, rheumatic myelitis, psoriasis, os...

Indication: Primary or secondary adrenocortical insufficiency; rheumatic & hematologic disorders; bronchial asthma; co...

Indication: Prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac & hepatic transplants in co...

Indication: Transplantation: Solid organ transplantation (kidney, liver, heart, combined heart-lung, lung, pancreas); bone...

1  /  2
Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.